Factors Associated With Benefit of Treatment of Patent Ductus Arteriosus in Preterm Infants
| Autor: | Esther J. S. Jansen, Tim Hundscheid, Wes Onland, Elisabeth M. W. Kooi, Peter Andriessen, Willem P. de Boode |
|---|---|
| Přispěvatelé: | School of Med. Physics and Eng. Eindhoven, EngD School AP |
| Jazyk: | angličtina |
| Rok vydání: | 2021 |
| Předmět: |
BIRTH-WEIGHT INFANTS
Pediatrics medicine.medical_specialty LOW-DOSE INDOMETHACIN genetic structures ductus botalli Birth weight patent ductus arteriosis Vascular damage Radboud Institute for Health Sciences [Radboudumc 16] Placebo-controlled study PLACEBO-CONTROLLED TRIAL INTRAVENOUS INDOMETHACIN EARLY CLOSURE law.invention PROPHYLACTIC INDOMETHACIN 03 medical and health sciences DOUBLE-BLIND 0302 clinical medicine Randomized controlled trial law 030225 pediatrics Ductus arteriosus medicine 030212 general & internal medicine PREMATURE-INFANTS acetaminophen ibuprofen business.industry lcsh:RJ1-570 lcsh:Pediatrics Retinopathy of prematurity indometacin medicine.disease INTRAVENTRICULAR HEMORRHAGE Low birth weight medicine.anatomical_structure Bronchopulmonary dysplasia Pediatrics Perinatology and Child Health Necrotizing enterocolitis Systematic Review premature (babies) medicine.symptom business |
| Zdroj: | Frontiers in Pediatrics Frontiers in Pediatrics, 9 Frontiers in Pediatrics, Vol 9 (2021) Frontiers in Pediatrics, 9:626262. Frontiers Media S.A. |
| ISSN: | 2296-2360 |
| DOI: | 10.3389/fped.2021.626262 |
| Popis: | Context:There is an ongoing debate on the optimal management of patent ductus arteriosus (PDA) in preterm infants. Identifying subgroup of infants who would benefit from pharmacological treatment might help.Objective:To investigate the modulating effect of the differences in methodological quality, the rate of open-label treatment, and patient characteristics on relevant outcome measures in randomized controlled trials (RCTs).Data Sources:Electronic database search between 1950 and May 2020.Study Selection:RCTs that assessed pharmacological treatment compared to placebo/no treatment.Data Extraction:Data is extracted following the PRISMA guidelines. Outcome measures were failure to ductal closure, surgical ligation, incidence of necrotizing enterocolitis, bronchopulmonary dysplasia, sepsis, periventricular leukomalacia, intraventricular hemorrhage (IVH) grade ≥3, retinopathy of prematurity and mortality.Results:Forty-seven studies were eligible. The incidence of IVH grade ≥3 was lower in the treated infants compared to the placebo/no treatment (RR 0.77, 95% CI 0.64–0.94) and in the subgroups of infants with either a gestational age Limitations:Statistical heterogeneity caused by missing data and variable definitions of outcome parameters.Conclusions:Although the quality of evidence is low, this meta-analysis suggests that pharmacological treatment of PDA reduces severe IVH in extremely preterm, extremely low birth weight infants or if treatment with indomethacin was started |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|